Polymyositis with mitochondrial pathology or atypical form of sporadic inclusion body myositis: case series and review of the literature

Rheumatol Int. 2019 Aug;39(8):1459-1466. doi: 10.1007/s00296-019-04314-8. Epub 2019 May 4.

Abstract

Polymyositis with mitochondrial pathology (PM-Mito) is a rare form of idiopathic inflammatory myopathy with no definite diagnostic criteria and similarities to both PM and sporadic inclusion body myositis (s-IBM). The aim of this study is to address the dilemma of whether PM-Mito is a subtype of inflammatory myopathy or represents a disease falling into the spectrum of s-IBM. Herein, we report four female patients diagnosed with PM-Mito, highlighting their rather atypical clinical and histopathological characteristics that seem to indicate a diagnosis away from s-IBM. Muscle weakness was rather proximal and symmetrical and lacked the selective pattern observed in s-IBM. Patients had large-scale deletions in mtDNA, reflecting the mitochondrial component in the pathology of the disease. Conclusively, our study adds to the limited data in the literature on whether PM-Mito is a distinct form of myositis or represents a prodromal stage of s-IBM. Although the latter seems to be supported by a substantial body of evidence, there are, however, important differences, such as the different patterns of muscle weakness, and the good response to treatment observed in some patients. Larger-scale studies are certainly needed to clarify pathogenesis and clinical characteristics of PM-Mito patients, especially in therapeutic and prognostic terms.

Keywords: Inclusion body myositis; Mitochondria; Polymyositis; mtDNA.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Aged
  • Biopsy
  • DNA, Mitochondrial / genetics
  • Diagnosis, Differential
  • Female
  • Gene Deletion
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Middle Aged
  • Mitochondria, Muscle / drug effects
  • Mitochondria, Muscle / genetics
  • Mitochondria, Muscle / pathology*
  • Muscle Weakness
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / pathology*
  • Muscle, Skeletal / physiopathology
  • Myositis, Inclusion Body / genetics
  • Myositis, Inclusion Body / pathology*
  • Myositis, Inclusion Body / physiopathology
  • Polymyositis / drug therapy
  • Polymyositis / genetics
  • Polymyositis / pathology*
  • Polymyositis / physiopathology
  • Predictive Value of Tests
  • Treatment Outcome

Substances

  • DNA, Mitochondrial
  • Glucocorticoids
  • Immunosuppressive Agents